New Approaches to Bioequivalence Assessment and Generic Approvals for Long Acting/Extended Release Antiretroviral Formulations
This workshop took place on Friday, September 20, 2024 and its aim was to to catalyze coordinated activity to identify the most efficient pathways for development and approval of generic antiretroviral LA/ER products and recommend appropriate ways to maximize the benefit these formulations will bring to these important and vulnerable populations.